Slingshot members are tracking this event:

Interim Analysis of REDUCE-IT Cardiovascular Outcomes Trial of Vescepa Expected Late 2016

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details A pre-specified interim efficacy and safety analysis was designed to be conducted upon achieving approximately 60% of the 1,612 aggregate primary cardiovascular events within the study. REDUCE-IT patients are in the process of completing a study visit over the next several months, after which additional time is required by the contract research organizations to finish collecting and preparing data for transfer to and analysis by the DMC.  The DMC's analysis is anticipated to occur in approximately six months.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 12, 2016
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Vascepa, Triglycerides, Statin Therapy, Icosapent Ethyl, Interim Analysis